TY  - JOUR
AU  - Rojo, Federico
AU  - Conde, Esther
AU  - Torres, Héctor
AU  - Cabezón-Gutiérrez, Luis
AU  - Bautista, Dolores
AU  - Ramos, Inmaculada
AU  - Carcedo, David
AU  - Arrabal, Natalia
AU  - García, J Francisco
AU  - Galán, Raquel
AU  - Nadal, Ernest
PY  - 2022
DO  - 10.1186/s12885-022-09397-4
UR  - http://hdl.handle.net/10668/20278
T2  - BMC cancer
AB  - Detection of the ROS1 rearrangement is mandatory in patients with advanced or metastatic non-small cell lung cancer (NSCLC) to allow targeted therapy with specific inhibitors. However, in Spanish clinical practice ROS1 determination is not yet fully...
LA  - en
KW  - Biomarker guided selection
KW  - C-ros oncogene 1
KW  - Cost-effectiveness analysis
KW  - Molecular testing
KW  - Non-small cell lung cancer
KW  - Biomarkers, Tumor
KW  - Biopsy
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Cost-Benefit Analysis
KW  - Female
KW  - Gene Rearrangement
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Molecular Diagnostic Techniques
KW  - Protein-Tyrosine Kinases
KW  - Proto-Oncogene Proteins
KW  - Quality-Adjusted Life Years
KW  - Spain
TI  - Clinical and economic impact of 'ROS1-testing' strategy compared to a 'no-ROS1-testing' strategy in advanced NSCLC in Spain.
TY  - research article
VL  - 22
ER  -